Slide 1: Microequities Microcap Conference June 2013
For personal use only Microequities Microcap Conference June 2013
Slide 2: Disclaimer
For personal use only DISCLAIMER The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe s
Slide 3: Strategic Vision
For personal use only STRATEGIC VISION Clover Corporation seeks to: • Identify, develop and commercialise speciality functional and nutritional ingredients in the growing nutraceutical & medical markets • Develop and commercialise leading edge proprietary and patented delivery technologies including
Slide 4: Company Description
For personal use only COMPANY DESCRIPTION • Focus on two business units: – Clover Corporation focuses on innovation, innovation obtaining the optimal return from proprietary technology and developing new business opportunities – Nu-Mega Ingredients (100% owned subsidiary) commercialises proprietary
Slide 5: Overview of Nu-Mega Operations
OVERVIEW OF NU-MEGA OPERATIONS For personal use only Maximize the use of proprietary bioactive delivery technology Algal & Tuna oil Other bioactives other oils Purchase from various sources Refine Medical & infant Emulsion formulations Tuna oil Infant formula, functional Microencapsulated foods & Po
Slide 6: Trading Update & Outlook for FY2013
For personal use only TRADING UPDATE & OUTLOOK FOR FY2013 • 12.5% increase in sales revenue in the first half FY2013 (pcp) – Increased sales in infant formula applications pp – Featuring Oceania and Asia • Re-signed 5 year supply contract with major multi-national infant formula manufacture. • Antic
Slide 7: Clover Half Year FY2013 Results
CLOVER HHalf lf Y Year FY2013 RESULTS For personal use only Period ended 31 January 2013 AUD $ million 1H FY2013 1H FY2012 Underlying to 31 January 2013 to 31 January 2012 1HFY2012 (as reported) (Unaudited, eliminating FFI cost) Revenue ($m) 20.2 17.9 17.9 Profit before tax ($m) 3.8 2.8 3.8 EBITDA (
Slide 8: Historical Financial Performance
HISTORICAL FINANCIAL For personal use only PERFORMANCE FY2012 FP2011 AUD million FY2010 # FY2009 FY2008 Adjusted (13 months) Shares on issue (m) 165.2 165.2 165.2 165.2 165.2 Total contributed 29.9 28.1 25.6 28.3 27.0 equity ($m) Cash total ($m) 9.7 7.4 12.2 9.2 10.8 Sales Revenue ($m) 38.4 35.6 34.
Slide 9: Continued Focus on Growth Markets & Value Added Products
CONTINUED FOCUS ON GROWTH MARKETS & VALUE ADDED For personal use only PRODUCTS FY2012 Geographic • Sales revenue increased with the strongest performance in Oceania. Oceania 26% • Focus has been on infant formula & Asia 64% children’s food applications. Europe 6% • In some mature infant formula mark
Slide 10: Delivery Systems Based on a Variety of Nutritional Bioactives
DELIVERY SYSTEMS BASED ON A VARIETY OF NUTRITIONAL BIOACTIVES For personal use only • Product portfolio includes refined tuna Sales Revenue based on oil and encapsulated powders containing Diversified Bioactives in FY2012 marine oil oil, algal oils, oils other specialty oils and important micronutri
Slide 11: Competitive Strengths – A Culture of Commercial Innovation
COMPETITIVE STRENGTHS – A CULTURE OF COMMERCIAL INNOVATION For personal use only • Clover’s core strengths; – Focus on value added markets – Proprietary & patented technology – C Commercial i l focus f on innovation i ti program – High quality differentiated products – Excellent reputation with clie
Slide 12: The Opportunities for Medical Food Applications
THE OPPORTUNITIES FOR MEDICAL FOOD APPLICATIONS For personal use only • Clover has supported strategic clinical studies for many years and this assists in identifying new commercial opportunities. • Medical issues that affect preterm infants include: – Cognitive or mental impairment. – Respiratory i
Slide 13: Preterm Infant Formulation
PRETERM INFANT FORMULATION For personal use only • Clover developed a specialty formulation for hospital use: – Licence agreements signed & patent applications filed. – Proprietary formulation & delivery system being manufactured for trials. – Successful clinical testing of the formulation and deliv
Slide 14: Thank You
For personal use only THANK YOU Questions? 14